Global Dyspnea Treatment Market

Dyspnea Treatment Comprehensive Study by Type (Therapy (Supplemental Oxygen Therapy, Relaxation Therapy), Drugs (Antianxiety Drugs, Antibiotics, Anticholinergic Agents, Corticosteroids, Others)), Application (Dissolve grime,, Remove stuck-on deposits, Even kill bacteria to sanitize with just water.), Route of Administration (Oral, Inhalation), End User (Hospitals, Home Care, Specialty Centers, Others) Players and Region - Global Market Outlook to 2029

Dyspnea Treatment Market by XX Submarkets | Forecast Years 2024-2029  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Dyspnea can hereby be defined as shortness of breath, which is also known as hunger for breath. The shortness of breath can range from mild to temporary and severe and persistent. This condition is most common in people with chronic lung or heart conditions such as asthma, pneumonia, myocardial ischemia, and others. It is also caused by the presence of environmental pollutants such as chemicals, fumes, dust, and smoke. Dyspnea can be caused by spending time at high altitudes, overexertion, or as a symptom of a number of other conditions. Signs of breathlessness are breathlessness due to exertion or illness; Difficulty breathing, rapid shallow breathing, palpitations, wheezing, coughing, chest tightness, and choking from difficulty breathing. The most common causes of dyspnea are heart failure, chronic obstructive pulmonary disease (COPD), pneumonia, asthma and interstitial lung disease, and psychogenic problems related to anxiety. According to statistics released by the Cleveland Clinic Center for Continuing Education, it is estimated that one in four people will experience shortness of breath at some point in their life. The existence of refined health infrastructure and the high demand for disease-specific novel therapies are the key factors for market growth.

AttributesDetails
Study Period2019-2029
Base Year2023
UnitValue (USD Million)
Key Companies ProfiledMayne Pharma Group Limited (Australia), Teva Pharmaceutical Industries Ltd. (Israel), GlaxoSmithKline plc (United Kingdom), Bausch Health (United States), Novartis AG (Switzerland), Hikma Pharmaceuticals plc (United Kingdom), Pfizer, Inc. (United States), Lannett Company, Inc. (United States), Amneal Pharmaceuticals LLC (United States), Mylan N.V. (United States), Lupin Limited (India) and ANI Pharmaceuticals, Inc. (United States)


This growth is primarily driven by A Rise in Prevalence of Dyspnea among the Population, Increasing Levels of Air Pollution, A Surge in Prevalence of Its Causative Symptoms Such As COPD and Asthma and Rise In Obesity among People, And Lifestyle Changes.

Globally, a noticeable market trend is evident Increase in Presence of Target Population Necessitates the Demand for Dyspnea Treatment Major Players, such as Mayne Pharma Group Limited (Australia), Teva Pharmaceutical Industries Ltd. (Israel), GlaxoSmithKline plc (United Kingdom), Bausch Health (United States), Novartis AG (Switzerland), Hikma Pharmaceuticals plc (United Kingdom), Pfizer, Inc. (United States), Lannett Company, Inc. (United States), Amneal Pharmaceuticals LLC (United States), Mylan N.V. (United States), Lupin Limited (India) and ANI Pharmaceuticals, Inc. (United States), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years. The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.

Key Developments in the Market:
In December , 2023 – Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Compay") announced positive topline results from the Company’s Phase 2 study evaluating Amiselimod, an investigative S1P antagonist, for the treatment of ulcerative colitis (UC).
In July 2022, OMRON Healthcare introduced its latest advancement in the Oxygen therapy category with the launch of a portable oxygen concentrator. The product is designed to aid the homecare providers when managing the therapy and lifestyle needs of nearly all patients with COPD and respiratory problems.

Influencing Trend:
Increase in Presence of Target Population Necessitates the Demand for Dyspnea Treatment and Increase in Product Approvals

Market Growth Drivers:
A Rise in Prevalence of Dyspnea among the Population, Increasing Levels of Air Pollution, A Surge in Prevalence of Its Causative Symptoms Such As COPD and Asthma and Rise In Obesity among People, And Lifestyle Changes

Challenges:
Limited Operating Revenue Opportunities for Players Focused On Developing Targeted Therapies for Dyspnea Treatment

Restraints:
Lack of Awareness among People

Opportunities:
Well-Established Health Care Infrastructure and Growing Focus of Governments of Countries in Enhancing Health Care Facilities

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints in Dyspnea Treatment Market
- Analysis about New Entrants in Dyspnea Treatment Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
- An Unbiased Perspective towards Market Performance & Indicators

Against this Challenging Backdrop, Dyspnea Treatment Study Sheds Light on
— The Dyspnea Treatment Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Dyspnea Treatment industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Dyspnea Treatment industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Therapy [Supplemental Oxygen Therapy, Relaxation Therapy]
  • Drugs [Antianxiety Drugs, Antibiotics, Anticholinergic Agents, Corticosteroids, Others]
By Application
  • dissolve grime,
  • remove stuck-on deposits
  • even kill bacteria to sanitize with just water.
By Route of Administration
  • Oral
  • Inhalation

By End User
  • Hospitals
  • Home Care
  • Specialty Centers
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. A Rise in Prevalence of Dyspnea among the Population
      • 3.2.2. Increasing Levels of Air Pollution
      • 3.2.3. A Surge in Prevalence of Its Causative Symptoms Such As COPD and Asthma
      • 3.2.4. Rise In Obesity among People, And Lifestyle Changes
    • 3.3. Market Challenges
      • 3.3.1. Limited Operating Revenue Opportunities for Players Focused On Developing Targeted Therapies for Dyspnea Treatment
    • 3.4. Market Trends
      • 3.4.1. Increase in Presence of Target Population Necessitates the Demand for Dyspnea Treatment
      • 3.4.2. Increase in Product Approvals
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Dyspnea Treatment, by Type, Application, Route of Administration, End User and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Dyspnea Treatment (Value)
      • 5.2.1. Global Dyspnea Treatment by: Type (Value)
        • 5.2.1.1. Therapy [Supplemental Oxygen Therapy, Relaxation Therapy]
        • 5.2.1.2. Drugs [Antianxiety Drugs, Antibiotics, Anticholinergic Agents, Corticosteroids, Others]
      • 5.2.2. Global Dyspnea Treatment by: Application (Value)
        • 5.2.2.1. Dissolve grime,
        • 5.2.2.2. Remove stuck-on deposits
        • 5.2.2.3. Even kill bacteria to sanitize with just water.
      • 5.2.3. Global Dyspnea Treatment by: Route of Administration (Value)
        • 5.2.3.1. Oral
        • 5.2.3.2. Inhalation
      • 5.2.4. Global Dyspnea Treatment by: End User (Value)
        • 5.2.4.1. Hospitals
        • 5.2.4.2. Home Care
        • 5.2.4.3. Specialty Centers
        • 5.2.4.4. Others
      • 5.2.5. Global Dyspnea Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Dyspnea Treatment (Price)
      • 5.3.1. Global Dyspnea Treatment by: Type (Price)
  • 6. Dyspnea Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Mayne Pharma Group Limited (Australia)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. GlaxoSmithKline plc (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bausch Health (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Novartis AG (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Hikma Pharmaceuticals plc (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Pfizer, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Lannett Company, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Amneal Pharmaceuticals LLC (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Mylan N.V. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Lupin Limited (India)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. ANI Pharmaceuticals, Inc. (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Dyspnea Treatment Sale, by Type, Application, Route of Administration, End User and Region (value and price ) (2024-2029)
    • 7.1. Introduction
    • 7.2. Global Dyspnea Treatment (Value)
      • 7.2.1. Global Dyspnea Treatment by: Type (Value)
        • 7.2.1.1. Therapy [Supplemental Oxygen Therapy, Relaxation Therapy]
        • 7.2.1.2. Drugs [Antianxiety Drugs, Antibiotics, Anticholinergic Agents, Corticosteroids, Others]
      • 7.2.2. Global Dyspnea Treatment by: Application (Value)
        • 7.2.2.1. Dissolve grime,
        • 7.2.2.2. Remove stuck-on deposits
        • 7.2.2.3. Even kill bacteria to sanitize with just water.
      • 7.2.3. Global Dyspnea Treatment by: Route of Administration (Value)
        • 7.2.3.1. Oral
        • 7.2.3.2. Inhalation
      • 7.2.4. Global Dyspnea Treatment by: End User (Value)
        • 7.2.4.1. Hospitals
        • 7.2.4.2. Home Care
        • 7.2.4.3. Specialty Centers
        • 7.2.4.4. Others
      • 7.2.5. Global Dyspnea Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Dyspnea Treatment (Price)
      • 7.3.1. Global Dyspnea Treatment by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Dyspnea Treatment: by Type(USD Million)
  • Table 2. Dyspnea Treatment Therapy [Supplemental Oxygen Therapy, Relaxation Therapy] , by Region USD Million (2018-2023)
  • Table 3. Dyspnea Treatment Drugs [Antianxiety Drugs, Antibiotics, Anticholinergic Agents, Corticosteroids, Others] , by Region USD Million (2018-2023)
  • Table 4. Dyspnea Treatment: by Application(USD Million)
  • Table 5. Dyspnea Treatment Dissolve grime, , by Region USD Million (2018-2023)
  • Table 6. Dyspnea Treatment Remove stuck-on deposits , by Region USD Million (2018-2023)
  • Table 7. Dyspnea Treatment Even kill bacteria to sanitize with just water. , by Region USD Million (2018-2023)
  • Table 8. Dyspnea Treatment: by Route of Administration(USD Million)
  • Table 9. Dyspnea Treatment Oral , by Region USD Million (2018-2023)
  • Table 10. Dyspnea Treatment Inhalation , by Region USD Million (2018-2023)
  • Table 11. Dyspnea Treatment: by End User(USD Million)
  • Table 12. Dyspnea Treatment Hospitals , by Region USD Million (2018-2023)
  • Table 13. Dyspnea Treatment Home Care , by Region USD Million (2018-2023)
  • Table 14. Dyspnea Treatment Specialty Centers , by Region USD Million (2018-2023)
  • Table 15. Dyspnea Treatment Others , by Region USD Million (2018-2023)
  • Table 16. South America Dyspnea Treatment, by Country USD Million (2018-2023)
  • Table 17. South America Dyspnea Treatment, by Type USD Million (2018-2023)
  • Table 18. South America Dyspnea Treatment, by Application USD Million (2018-2023)
  • Table 19. South America Dyspnea Treatment, by Route of Administration USD Million (2018-2023)
  • Table 20. South America Dyspnea Treatment, by End User USD Million (2018-2023)
  • Table 21. Brazil Dyspnea Treatment, by Type USD Million (2018-2023)
  • Table 22. Brazil Dyspnea Treatment, by Application USD Million (2018-2023)
  • Table 23. Brazil Dyspnea Treatment, by Route of Administration USD Million (2018-2023)
  • Table 24. Brazil Dyspnea Treatment, by End User USD Million (2018-2023)
  • Table 25. Argentina Dyspnea Treatment, by Type USD Million (2018-2023)
  • Table 26. Argentina Dyspnea Treatment, by Application USD Million (2018-2023)
  • Table 27. Argentina Dyspnea Treatment, by Route of Administration USD Million (2018-2023)
  • Table 28. Argentina Dyspnea Treatment, by End User USD Million (2018-2023)
  • Table 29. Rest of South America Dyspnea Treatment, by Type USD Million (2018-2023)
  • Table 30. Rest of South America Dyspnea Treatment, by Application USD Million (2018-2023)
  • Table 31. Rest of South America Dyspnea Treatment, by Route of Administration USD Million (2018-2023)
  • Table 32. Rest of South America Dyspnea Treatment, by End User USD Million (2018-2023)
  • Table 33. Asia Pacific Dyspnea Treatment, by Country USD Million (2018-2023)
  • Table 34. Asia Pacific Dyspnea Treatment, by Type USD Million (2018-2023)
  • Table 35. Asia Pacific Dyspnea Treatment, by Application USD Million (2018-2023)
  • Table 36. Asia Pacific Dyspnea Treatment, by Route of Administration USD Million (2018-2023)
  • Table 37. Asia Pacific Dyspnea Treatment, by End User USD Million (2018-2023)
  • Table 38. China Dyspnea Treatment, by Type USD Million (2018-2023)
  • Table 39. China Dyspnea Treatment, by Application USD Million (2018-2023)
  • Table 40. China Dyspnea Treatment, by Route of Administration USD Million (2018-2023)
  • Table 41. China Dyspnea Treatment, by End User USD Million (2018-2023)
  • Table 42. Japan Dyspnea Treatment, by Type USD Million (2018-2023)
  • Table 43. Japan Dyspnea Treatment, by Application USD Million (2018-2023)
  • Table 44. Japan Dyspnea Treatment, by Route of Administration USD Million (2018-2023)
  • Table 45. Japan Dyspnea Treatment, by End User USD Million (2018-2023)
  • Table 46. India Dyspnea Treatment, by Type USD Million (2018-2023)
  • Table 47. India Dyspnea Treatment, by Application USD Million (2018-2023)
  • Table 48. India Dyspnea Treatment, by Route of Administration USD Million (2018-2023)
  • Table 49. India Dyspnea Treatment, by End User USD Million (2018-2023)
  • Table 50. South Korea Dyspnea Treatment, by Type USD Million (2018-2023)
  • Table 51. South Korea Dyspnea Treatment, by Application USD Million (2018-2023)
  • Table 52. South Korea Dyspnea Treatment, by Route of Administration USD Million (2018-2023)
  • Table 53. South Korea Dyspnea Treatment, by End User USD Million (2018-2023)
  • Table 54. Taiwan Dyspnea Treatment, by Type USD Million (2018-2023)
  • Table 55. Taiwan Dyspnea Treatment, by Application USD Million (2018-2023)
  • Table 56. Taiwan Dyspnea Treatment, by Route of Administration USD Million (2018-2023)
  • Table 57. Taiwan Dyspnea Treatment, by End User USD Million (2018-2023)
  • Table 58. Australia Dyspnea Treatment, by Type USD Million (2018-2023)
  • Table 59. Australia Dyspnea Treatment, by Application USD Million (2018-2023)
  • Table 60. Australia Dyspnea Treatment, by Route of Administration USD Million (2018-2023)
  • Table 61. Australia Dyspnea Treatment, by End User USD Million (2018-2023)
  • Table 62. Rest of Asia-Pacific Dyspnea Treatment, by Type USD Million (2018-2023)
  • Table 63. Rest of Asia-Pacific Dyspnea Treatment, by Application USD Million (2018-2023)
  • Table 64. Rest of Asia-Pacific Dyspnea Treatment, by Route of Administration USD Million (2018-2023)
  • Table 65. Rest of Asia-Pacific Dyspnea Treatment, by End User USD Million (2018-2023)
  • Table 66. Europe Dyspnea Treatment, by Country USD Million (2018-2023)
  • Table 67. Europe Dyspnea Treatment, by Type USD Million (2018-2023)
  • Table 68. Europe Dyspnea Treatment, by Application USD Million (2018-2023)
  • Table 69. Europe Dyspnea Treatment, by Route of Administration USD Million (2018-2023)
  • Table 70. Europe Dyspnea Treatment, by End User USD Million (2018-2023)
  • Table 71. Germany Dyspnea Treatment, by Type USD Million (2018-2023)
  • Table 72. Germany Dyspnea Treatment, by Application USD Million (2018-2023)
  • Table 73. Germany Dyspnea Treatment, by Route of Administration USD Million (2018-2023)
  • Table 74. Germany Dyspnea Treatment, by End User USD Million (2018-2023)
  • Table 75. France Dyspnea Treatment, by Type USD Million (2018-2023)
  • Table 76. France Dyspnea Treatment, by Application USD Million (2018-2023)
  • Table 77. France Dyspnea Treatment, by Route of Administration USD Million (2018-2023)
  • Table 78. France Dyspnea Treatment, by End User USD Million (2018-2023)
  • Table 79. Italy Dyspnea Treatment, by Type USD Million (2018-2023)
  • Table 80. Italy Dyspnea Treatment, by Application USD Million (2018-2023)
  • Table 81. Italy Dyspnea Treatment, by Route of Administration USD Million (2018-2023)
  • Table 82. Italy Dyspnea Treatment, by End User USD Million (2018-2023)
  • Table 83. United Kingdom Dyspnea Treatment, by Type USD Million (2018-2023)
  • Table 84. United Kingdom Dyspnea Treatment, by Application USD Million (2018-2023)
  • Table 85. United Kingdom Dyspnea Treatment, by Route of Administration USD Million (2018-2023)
  • Table 86. United Kingdom Dyspnea Treatment, by End User USD Million (2018-2023)
  • Table 87. Netherlands Dyspnea Treatment, by Type USD Million (2018-2023)
  • Table 88. Netherlands Dyspnea Treatment, by Application USD Million (2018-2023)
  • Table 89. Netherlands Dyspnea Treatment, by Route of Administration USD Million (2018-2023)
  • Table 90. Netherlands Dyspnea Treatment, by End User USD Million (2018-2023)
  • Table 91. Rest of Europe Dyspnea Treatment, by Type USD Million (2018-2023)
  • Table 92. Rest of Europe Dyspnea Treatment, by Application USD Million (2018-2023)
  • Table 93. Rest of Europe Dyspnea Treatment, by Route of Administration USD Million (2018-2023)
  • Table 94. Rest of Europe Dyspnea Treatment, by End User USD Million (2018-2023)
  • Table 95. MEA Dyspnea Treatment, by Country USD Million (2018-2023)
  • Table 96. MEA Dyspnea Treatment, by Type USD Million (2018-2023)
  • Table 97. MEA Dyspnea Treatment, by Application USD Million (2018-2023)
  • Table 98. MEA Dyspnea Treatment, by Route of Administration USD Million (2018-2023)
  • Table 99. MEA Dyspnea Treatment, by End User USD Million (2018-2023)
  • Table 100. Middle East Dyspnea Treatment, by Type USD Million (2018-2023)
  • Table 101. Middle East Dyspnea Treatment, by Application USD Million (2018-2023)
  • Table 102. Middle East Dyspnea Treatment, by Route of Administration USD Million (2018-2023)
  • Table 103. Middle East Dyspnea Treatment, by End User USD Million (2018-2023)
  • Table 104. Africa Dyspnea Treatment, by Type USD Million (2018-2023)
  • Table 105. Africa Dyspnea Treatment, by Application USD Million (2018-2023)
  • Table 106. Africa Dyspnea Treatment, by Route of Administration USD Million (2018-2023)
  • Table 107. Africa Dyspnea Treatment, by End User USD Million (2018-2023)
  • Table 108. North America Dyspnea Treatment, by Country USD Million (2018-2023)
  • Table 109. North America Dyspnea Treatment, by Type USD Million (2018-2023)
  • Table 110. North America Dyspnea Treatment, by Application USD Million (2018-2023)
  • Table 111. North America Dyspnea Treatment, by Route of Administration USD Million (2018-2023)
  • Table 112. North America Dyspnea Treatment, by End User USD Million (2018-2023)
  • Table 113. United States Dyspnea Treatment, by Type USD Million (2018-2023)
  • Table 114. United States Dyspnea Treatment, by Application USD Million (2018-2023)
  • Table 115. United States Dyspnea Treatment, by Route of Administration USD Million (2018-2023)
  • Table 116. United States Dyspnea Treatment, by End User USD Million (2018-2023)
  • Table 117. Canada Dyspnea Treatment, by Type USD Million (2018-2023)
  • Table 118. Canada Dyspnea Treatment, by Application USD Million (2018-2023)
  • Table 119. Canada Dyspnea Treatment, by Route of Administration USD Million (2018-2023)
  • Table 120. Canada Dyspnea Treatment, by End User USD Million (2018-2023)
  • Table 121. Mexico Dyspnea Treatment, by Type USD Million (2018-2023)
  • Table 122. Mexico Dyspnea Treatment, by Application USD Million (2018-2023)
  • Table 123. Mexico Dyspnea Treatment, by Route of Administration USD Million (2018-2023)
  • Table 124. Mexico Dyspnea Treatment, by End User USD Million (2018-2023)
  • Table 125. Dyspnea Treatment: by Type(USD/Units)
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Dyspnea Treatment: by Type(USD Million)
  • Table 139. Dyspnea Treatment Therapy [Supplemental Oxygen Therapy, Relaxation Therapy] , by Region USD Million (2024-2029)
  • Table 140. Dyspnea Treatment Drugs [Antianxiety Drugs, Antibiotics, Anticholinergic Agents, Corticosteroids, Others] , by Region USD Million (2024-2029)
  • Table 141. Dyspnea Treatment: by Application(USD Million)
  • Table 142. Dyspnea Treatment Dissolve grime, , by Region USD Million (2024-2029)
  • Table 143. Dyspnea Treatment Remove stuck-on deposits , by Region USD Million (2024-2029)
  • Table 144. Dyspnea Treatment Even kill bacteria to sanitize with just water. , by Region USD Million (2024-2029)
  • Table 145. Dyspnea Treatment: by Route of Administration(USD Million)
  • Table 146. Dyspnea Treatment Oral , by Region USD Million (2024-2029)
  • Table 147. Dyspnea Treatment Inhalation , by Region USD Million (2024-2029)
  • Table 148. Dyspnea Treatment: by End User(USD Million)
  • Table 149. Dyspnea Treatment Hospitals , by Region USD Million (2024-2029)
  • Table 150. Dyspnea Treatment Home Care , by Region USD Million (2024-2029)
  • Table 151. Dyspnea Treatment Specialty Centers , by Region USD Million (2024-2029)
  • Table 152. Dyspnea Treatment Others , by Region USD Million (2024-2029)
  • Table 153. South America Dyspnea Treatment, by Country USD Million (2024-2029)
  • Table 154. South America Dyspnea Treatment, by Type USD Million (2024-2029)
  • Table 155. South America Dyspnea Treatment, by Application USD Million (2024-2029)
  • Table 156. South America Dyspnea Treatment, by Route of Administration USD Million (2024-2029)
  • Table 157. South America Dyspnea Treatment, by End User USD Million (2024-2029)
  • Table 158. Brazil Dyspnea Treatment, by Type USD Million (2024-2029)
  • Table 159. Brazil Dyspnea Treatment, by Application USD Million (2024-2029)
  • Table 160. Brazil Dyspnea Treatment, by Route of Administration USD Million (2024-2029)
  • Table 161. Brazil Dyspnea Treatment, by End User USD Million (2024-2029)
  • Table 162. Argentina Dyspnea Treatment, by Type USD Million (2024-2029)
  • Table 163. Argentina Dyspnea Treatment, by Application USD Million (2024-2029)
  • Table 164. Argentina Dyspnea Treatment, by Route of Administration USD Million (2024-2029)
  • Table 165. Argentina Dyspnea Treatment, by End User USD Million (2024-2029)
  • Table 166. Rest of South America Dyspnea Treatment, by Type USD Million (2024-2029)
  • Table 167. Rest of South America Dyspnea Treatment, by Application USD Million (2024-2029)
  • Table 168. Rest of South America Dyspnea Treatment, by Route of Administration USD Million (2024-2029)
  • Table 169. Rest of South America Dyspnea Treatment, by End User USD Million (2024-2029)
  • Table 170. Asia Pacific Dyspnea Treatment, by Country USD Million (2024-2029)
  • Table 171. Asia Pacific Dyspnea Treatment, by Type USD Million (2024-2029)
  • Table 172. Asia Pacific Dyspnea Treatment, by Application USD Million (2024-2029)
  • Table 173. Asia Pacific Dyspnea Treatment, by Route of Administration USD Million (2024-2029)
  • Table 174. Asia Pacific Dyspnea Treatment, by End User USD Million (2024-2029)
  • Table 175. China Dyspnea Treatment, by Type USD Million (2024-2029)
  • Table 176. China Dyspnea Treatment, by Application USD Million (2024-2029)
  • Table 177. China Dyspnea Treatment, by Route of Administration USD Million (2024-2029)
  • Table 178. China Dyspnea Treatment, by End User USD Million (2024-2029)
  • Table 179. Japan Dyspnea Treatment, by Type USD Million (2024-2029)
  • Table 180. Japan Dyspnea Treatment, by Application USD Million (2024-2029)
  • Table 181. Japan Dyspnea Treatment, by Route of Administration USD Million (2024-2029)
  • Table 182. Japan Dyspnea Treatment, by End User USD Million (2024-2029)
  • Table 183. India Dyspnea Treatment, by Type USD Million (2024-2029)
  • Table 184. India Dyspnea Treatment, by Application USD Million (2024-2029)
  • Table 185. India Dyspnea Treatment, by Route of Administration USD Million (2024-2029)
  • Table 186. India Dyspnea Treatment, by End User USD Million (2024-2029)
  • Table 187. South Korea Dyspnea Treatment, by Type USD Million (2024-2029)
  • Table 188. South Korea Dyspnea Treatment, by Application USD Million (2024-2029)
  • Table 189. South Korea Dyspnea Treatment, by Route of Administration USD Million (2024-2029)
  • Table 190. South Korea Dyspnea Treatment, by End User USD Million (2024-2029)
  • Table 191. Taiwan Dyspnea Treatment, by Type USD Million (2024-2029)
  • Table 192. Taiwan Dyspnea Treatment, by Application USD Million (2024-2029)
  • Table 193. Taiwan Dyspnea Treatment, by Route of Administration USD Million (2024-2029)
  • Table 194. Taiwan Dyspnea Treatment, by End User USD Million (2024-2029)
  • Table 195. Australia Dyspnea Treatment, by Type USD Million (2024-2029)
  • Table 196. Australia Dyspnea Treatment, by Application USD Million (2024-2029)
  • Table 197. Australia Dyspnea Treatment, by Route of Administration USD Million (2024-2029)
  • Table 198. Australia Dyspnea Treatment, by End User USD Million (2024-2029)
  • Table 199. Rest of Asia-Pacific Dyspnea Treatment, by Type USD Million (2024-2029)
  • Table 200. Rest of Asia-Pacific Dyspnea Treatment, by Application USD Million (2024-2029)
  • Table 201. Rest of Asia-Pacific Dyspnea Treatment, by Route of Administration USD Million (2024-2029)
  • Table 202. Rest of Asia-Pacific Dyspnea Treatment, by End User USD Million (2024-2029)
  • Table 203. Europe Dyspnea Treatment, by Country USD Million (2024-2029)
  • Table 204. Europe Dyspnea Treatment, by Type USD Million (2024-2029)
  • Table 205. Europe Dyspnea Treatment, by Application USD Million (2024-2029)
  • Table 206. Europe Dyspnea Treatment, by Route of Administration USD Million (2024-2029)
  • Table 207. Europe Dyspnea Treatment, by End User USD Million (2024-2029)
  • Table 208. Germany Dyspnea Treatment, by Type USD Million (2024-2029)
  • Table 209. Germany Dyspnea Treatment, by Application USD Million (2024-2029)
  • Table 210. Germany Dyspnea Treatment, by Route of Administration USD Million (2024-2029)
  • Table 211. Germany Dyspnea Treatment, by End User USD Million (2024-2029)
  • Table 212. France Dyspnea Treatment, by Type USD Million (2024-2029)
  • Table 213. France Dyspnea Treatment, by Application USD Million (2024-2029)
  • Table 214. France Dyspnea Treatment, by Route of Administration USD Million (2024-2029)
  • Table 215. France Dyspnea Treatment, by End User USD Million (2024-2029)
  • Table 216. Italy Dyspnea Treatment, by Type USD Million (2024-2029)
  • Table 217. Italy Dyspnea Treatment, by Application USD Million (2024-2029)
  • Table 218. Italy Dyspnea Treatment, by Route of Administration USD Million (2024-2029)
  • Table 219. Italy Dyspnea Treatment, by End User USD Million (2024-2029)
  • Table 220. United Kingdom Dyspnea Treatment, by Type USD Million (2024-2029)
  • Table 221. United Kingdom Dyspnea Treatment, by Application USD Million (2024-2029)
  • Table 222. United Kingdom Dyspnea Treatment, by Route of Administration USD Million (2024-2029)
  • Table 223. United Kingdom Dyspnea Treatment, by End User USD Million (2024-2029)
  • Table 224. Netherlands Dyspnea Treatment, by Type USD Million (2024-2029)
  • Table 225. Netherlands Dyspnea Treatment, by Application USD Million (2024-2029)
  • Table 226. Netherlands Dyspnea Treatment, by Route of Administration USD Million (2024-2029)
  • Table 227. Netherlands Dyspnea Treatment, by End User USD Million (2024-2029)
  • Table 228. Rest of Europe Dyspnea Treatment, by Type USD Million (2024-2029)
  • Table 229. Rest of Europe Dyspnea Treatment, by Application USD Million (2024-2029)
  • Table 230. Rest of Europe Dyspnea Treatment, by Route of Administration USD Million (2024-2029)
  • Table 231. Rest of Europe Dyspnea Treatment, by End User USD Million (2024-2029)
  • Table 232. MEA Dyspnea Treatment, by Country USD Million (2024-2029)
  • Table 233. MEA Dyspnea Treatment, by Type USD Million (2024-2029)
  • Table 234. MEA Dyspnea Treatment, by Application USD Million (2024-2029)
  • Table 235. MEA Dyspnea Treatment, by Route of Administration USD Million (2024-2029)
  • Table 236. MEA Dyspnea Treatment, by End User USD Million (2024-2029)
  • Table 237. Middle East Dyspnea Treatment, by Type USD Million (2024-2029)
  • Table 238. Middle East Dyspnea Treatment, by Application USD Million (2024-2029)
  • Table 239. Middle East Dyspnea Treatment, by Route of Administration USD Million (2024-2029)
  • Table 240. Middle East Dyspnea Treatment, by End User USD Million (2024-2029)
  • Table 241. Africa Dyspnea Treatment, by Type USD Million (2024-2029)
  • Table 242. Africa Dyspnea Treatment, by Application USD Million (2024-2029)
  • Table 243. Africa Dyspnea Treatment, by Route of Administration USD Million (2024-2029)
  • Table 244. Africa Dyspnea Treatment, by End User USD Million (2024-2029)
  • Table 245. North America Dyspnea Treatment, by Country USD Million (2024-2029)
  • Table 246. North America Dyspnea Treatment, by Type USD Million (2024-2029)
  • Table 247. North America Dyspnea Treatment, by Application USD Million (2024-2029)
  • Table 248. North America Dyspnea Treatment, by Route of Administration USD Million (2024-2029)
  • Table 249. North America Dyspnea Treatment, by End User USD Million (2024-2029)
  • Table 250. United States Dyspnea Treatment, by Type USD Million (2024-2029)
  • Table 251. United States Dyspnea Treatment, by Application USD Million (2024-2029)
  • Table 252. United States Dyspnea Treatment, by Route of Administration USD Million (2024-2029)
  • Table 253. United States Dyspnea Treatment, by End User USD Million (2024-2029)
  • Table 254. Canada Dyspnea Treatment, by Type USD Million (2024-2029)
  • Table 255. Canada Dyspnea Treatment, by Application USD Million (2024-2029)
  • Table 256. Canada Dyspnea Treatment, by Route of Administration USD Million (2024-2029)
  • Table 257. Canada Dyspnea Treatment, by End User USD Million (2024-2029)
  • Table 258. Mexico Dyspnea Treatment, by Type USD Million (2024-2029)
  • Table 259. Mexico Dyspnea Treatment, by Application USD Million (2024-2029)
  • Table 260. Mexico Dyspnea Treatment, by Route of Administration USD Million (2024-2029)
  • Table 261. Mexico Dyspnea Treatment, by End User USD Million (2024-2029)
  • Table 262. Dyspnea Treatment: by Type(USD/Units)
  • Table 263. Research Programs/Design for This Report
  • Table 264. Key Data Information from Secondary Sources
  • Table 265. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Dyspnea Treatment: by Type USD Million (2018-2023)
  • Figure 5. Global Dyspnea Treatment: by Application USD Million (2018-2023)
  • Figure 6. Global Dyspnea Treatment: by Route of Administration USD Million (2018-2023)
  • Figure 7. Global Dyspnea Treatment: by End User USD Million (2018-2023)
  • Figure 8. South America Dyspnea Treatment Share (%), by Country
  • Figure 9. Asia Pacific Dyspnea Treatment Share (%), by Country
  • Figure 10. Europe Dyspnea Treatment Share (%), by Country
  • Figure 11. MEA Dyspnea Treatment Share (%), by Country
  • Figure 12. North America Dyspnea Treatment Share (%), by Country
  • Figure 13. Global Dyspnea Treatment: by Type USD/Units (2018-2023)
  • Figure 14. Global Dyspnea Treatment share by Players 2023 (%)
  • Figure 15. Global Dyspnea Treatment share by Players (Top 3) 2023(%)
  • Figure 16. Global Dyspnea Treatment share by Players (Top 5) 2023(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Mayne Pharma Group Limited (Australia) Revenue, Net Income and Gross profit
  • Figure 19. Mayne Pharma Group Limited (Australia) Revenue: by Geography 2023
  • Figure 20. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 21. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2023
  • Figure 22. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 23. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2023
  • Figure 24. Bausch Health (United States) Revenue, Net Income and Gross profit
  • Figure 25. Bausch Health (United States) Revenue: by Geography 2023
  • Figure 26. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 27. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 28. Hikma Pharmaceuticals plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 29. Hikma Pharmaceuticals plc (United Kingdom) Revenue: by Geography 2023
  • Figure 30. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Pfizer, Inc. (United States) Revenue: by Geography 2023
  • Figure 32. Lannett Company, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. Lannett Company, Inc. (United States) Revenue: by Geography 2023
  • Figure 34. Amneal Pharmaceuticals LLC (United States) Revenue, Net Income and Gross profit
  • Figure 35. Amneal Pharmaceuticals LLC (United States) Revenue: by Geography 2023
  • Figure 36. Mylan N.V. (United States) Revenue, Net Income and Gross profit
  • Figure 37. Mylan N.V. (United States) Revenue: by Geography 2023
  • Figure 38. Lupin Limited (India) Revenue, Net Income and Gross profit
  • Figure 39. Lupin Limited (India) Revenue: by Geography 2023
  • Figure 40. ANI Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 41. ANI Pharmaceuticals, Inc. (United States) Revenue: by Geography 2023
  • Figure 42. Global Dyspnea Treatment: by Type USD Million (2024-2029)
  • Figure 43. Global Dyspnea Treatment: by Application USD Million (2024-2029)
  • Figure 44. Global Dyspnea Treatment: by Route of Administration USD Million (2024-2029)
  • Figure 45. Global Dyspnea Treatment: by End User USD Million (2024-2029)
  • Figure 46. South America Dyspnea Treatment Share (%), by Country
  • Figure 47. Asia Pacific Dyspnea Treatment Share (%), by Country
  • Figure 48. Europe Dyspnea Treatment Share (%), by Country
  • Figure 49. MEA Dyspnea Treatment Share (%), by Country
  • Figure 50. North America Dyspnea Treatment Share (%), by Country
  • Figure 51. Global Dyspnea Treatment: by Type USD/Units (2024-2029)
List of companies from research coverage that are profiled in the study
  • Mayne Pharma Group Limited (Australia)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • GlaxoSmithKline plc (United Kingdom)
  • Bausch Health (United States)
  • Novartis AG (Switzerland)
  • Hikma Pharmaceuticals plc (United Kingdom)
  • Pfizer, Inc. (United States)
  • Lannett Company, Inc. (United States)
  • Amneal Pharmaceuticals LLC (United States)
  • Mylan N.V. (United States)
  • Lupin Limited (India)
  • ANI Pharmaceuticals, Inc. (United States)
Additional players considered in the study are as follows:
Sun Pharmaceutical Industries Ltd. (India) , Nephron Pharmaceuticals Corporation (United States) , Aurobindo Pharma (India)
Select User Access Type

Key Highlights of Report


Jan 2024 215 Pages 69 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Dyspnea Treatment Market Quantitative research analysis
Global Dyspnea Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Dyspnea Treatment market are Mayne Pharma Group Limited (Australia), Teva Pharmaceutical Industries Ltd. (Israel), GlaxoSmithKline plc (United Kingdom), Bausch Health (United States), Novartis AG (Switzerland), Hikma Pharmaceuticals plc (United Kingdom), Pfizer, Inc. (United States), Lannett Company, Inc. (United States), Amneal Pharmaceuticals LLC (United States), Mylan N.V. (United States), Lupin Limited (India) and ANI Pharmaceuticals, Inc. (United States), to name a few.
is dominating the Dyspnea Treatment Market.
"Limited Operating Revenue Opportunities for Players Focused On Developing Targeted Therapies for Dyspnea Treatment" is seen as one of the major challenges by many Industry Players of Dyspnea Treatment Market
The Dyspnea Treatment market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get complete companies available in our research coverage.
The Dyspnea Treatment market is expected to see a steady growth rate during projected year 2023 to 2029.

Know More About Global Dyspnea Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Reflux Nephropathy Treatment Comprehensive Study by Type (Prophylactic Antibiotics, Antihypertensive Medications, Pain Medications, Others), Distribution Channel (Hospitals Pharmacies, Retail Pharmac...
$ 3350
Reperfusion Injury Comprehensive Study by Application (Heart Injury, Kidney Injury, Intestine Injury, Others), Treatment Type (Therapeutic Hypothermia, Cyclosporin, Stem Cell Therapy, Hydrogen Sulfid...
$ 3450
Cartilage Regeneration Technology Comprehensive Study by Application (Hyaline Cartilage, Fibrocartilage), Treatment (Cell-based (Chondrocyte Transplantation, Stem Cells, Growth Factors), Non-cell-bas...
$ 3650
Wolfram Syndrome Treatment  Comprehensive Study by Type (WFS1 gene (Type 1), WFS2 gene (Type 2)), Application (Retail Pharmacies, E-commerce, Hospital Pharmacies), Treatment (Gene Therapy, Regenerati...
$ 3650
Buerger’s Disease Diagnosis Comprehensive Study by Type (Blood Tests, The Allen’s Test, Angiogram (CT Scan, MRI Scan, X-Ray, Others), Tissue Biopsy, Others), Treatment (Smoking Cessation, Other Treat...
$ 3750
Raynaud’s Phenomenon Management Comprehensive Study by Test (Antinuclear Antibodies Test, Erythrocyte Sedimentation Rate Test, C-reactive Protein Test, Others), Treatment Type (Medication (Calcium Ch...
$ 3450